Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Mild parenchymal lung disease is still lung disease

Laurent Godinas, Sergio Harari, Joan A. Barberà, David Montani
European Respiratory Journal 2020 56: 2003542; DOI: 10.1183/13993003.03542-2020
Laurent Godinas
1Dept of Respiratory Diseases, UZ Leuven, Campus Gasthuisberg, Leuven, Belgium
2Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Dept CHROMETA, KU Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurent Godinas
Sergio Harari
3Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy
4Dept of Medical Sciences, Ospedale San Giuseppe, MultiMedica IRCCS, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sergio Harari
Joan A. Barberà
5Respiratory Institute, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Montani
6Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
7Assistance Publique - Hôpitaux de Paris (AP-HP), Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
8INSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Montani
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

PAH patients with mild parenchymal disease/low DLCO should be considered as group 3 patients with pulmonary vascular phenotype https://bit.ly/33awS0J

To the Editor:

We read with interest the article by Lewis et al. [1], which reports an increased mortality in patients with idiopathic pulmonary arterial hypertension (IPAH) and mild impairment in computed tomography (CT). They also show that low diffusing capacity of the lung for carbon monoxide (DLCO) was associated with worse outcomes. It is an important paper pointing out interesting issues on which we would like to comment.

PAH was originally described and classified as a pulmonary vascular disease with specific histopathological pattern: the plexogenic pulmonary arteriopathy, distinguishing it from other causes of pulmonary hypertension (PH). This morphological classification was replaced by a more clinical approach, which is still used presently, although updated classifications still bear the marks of the first attempt to categorise pulmonary vascular disease. Moreover, the term idiopathic refers to the complete absence of identifiable aetiology, including the absence of chronic lung disease (CLD), otherwise referred to CLD-associated PH [2].

Lewis reported a cohort of PAH patients presenting minor or mild lung parenchymal alterations in the group termed IPAHmild-LD. As compared to classical IPAH, this so-called “IPAHmild-LD” patients were characterised by older age (70 versus 53 years old); a male predominance (sex ratio of females to males of 3 for IPAH), high tobacco exposure (>80% current smokers), lower exertional capacity and lower DLCO. Contrarily to IPAH, these patients did not respond to specific PAH therapies in terms of walking distance or quality of life, and had a very poor prognosis despite treatment. All these characteristics are highly suggestive of a CLD-PH phenotype rather than IPAH. Indeed, it has been demonstrated that there is no clear correlation between pulmonary function tests (PFTs) and severity of PH in CLD [2]. This discrepancy has been highlighted in combined pulmonary fibrosis and emphysema (CPFE), which usually associates normal or sub-normal volumes and flows on PFTs, very low DLCO and frequent severe PH [3]. Interestingly, CPFE may represent 14% of the cohort of IPAHmild-LD reported by Lewis et al. [1]. We strongly believe that the association of abnormal chest CT with extremely low DLCO in a senior male population exposed to cigarette smoke indicates significant intrinsic lung disease associated with PH.

Therefore, in our opinion, these patients should be considered as having CLD-PH instead of IPAH. In recent years, evidences have surfaced indicating that there exists a specific “pulmonary vascular phenotype” among patients with PH [2], with particular clinical characteristics and different prognosis, suggesting that they are not a continuum with IPAH but a different entity, closer to CLD-PH than IPAH. Patients with the pulmonary vascular phenotype exhibit a low DLCO, which has been shown to be an independent prognostic marker in PAH [4]. Furthermore, Trip et al. [5] demonstrated that PAH patients with a DLCO <45% exhibited an atypical phenotype with worse outcome and poor response to PAH-specific therapies. They were mainly older men with history of cigarette exposure. This particular phenotype was also retrieved in other cohorts and interestingly some authors noted that those patients had similarities with CPFE patients in terms of prognosis, lung function, demographic characteristics and toxic exposure [6]. Moreover, similar findings were also found in post-capillary PH, low DLCO being associated with older age, male gender, poor survival, lower blood oxygenation and, again, higher cigarette smoke exposure and higher rate of CT abnormalities [7].

Conversely, it has been shown that patients with COPD and severe PH could also present analogous abnormalities with low DLCO and low arterial carbon dioxide tension for a relatively mild obstructive impairment [8]. It was also recently shown that low DLCO was a prognostic factor of survival in COPD with PH [9]. Similar findings were also retrieved in idiopathic pulmonary fibrosis, with the association of low DLCO with severe PH as a prognostic marker [10]. The presence of a low DLCO in pulmonary vascular diseases suggests an alteration of the alveolo-capillary compartment, with diffusion capacity being determined by the blood capillary volume and the alveolar membrane diffusion components [11]. The pulmonary vascular phenotype could be due to a vanishing capillary pulmonary syndrome [12], where toxic exposure could play a major role as shown in experimental studies in mice, demonstrating that emphysema and PH development are not systematically linked and could occur independently [13]. The characterisation of this phenotype shows that it behaves more like CLD-PH than true IPAH, regarding its epidemiological, radiological, functional and clinical features. Considering this increasing amount of data concerning the pulmonary vascular phenotype in CLD, we agree with Lewis et al. [1] in that patients who have traits of lung disease have a phenotype different from IPAH, and therefore should not be considered as having IPAH, despite fulfilling conventional criteria. Clinical trials focused on this particular group of patients is a crucial need. Adequate and early recognition of the pulmonary vascular phenotype is not only a matter of semantics and taxonomy, it is also clinically relevant due to poor response to treatment, and would provide the possibility of avoiding inefficient or harmful treatment, and need for early referral to lung transplantation.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-03542-2020.Shareable

Acknowledgements

This article was written on behalf of the PHAROS Clinical Research Collaboration members.

Footnotes

  • Conflict of interest: L. Godinas has nothing to disclose.

  • Conflict of interest: S. Harari has nothing to disclose.

  • Conflict of interest: J.A. Barberà has nothing to disclose.

  • Conflict of interest: D. Montani reports grants and personal fees from Actelion and Bayer, personal fees from GSK, Pfizer, Chiesi and Boehringer, grants, personal fees and non-financial support from MSD, non-financial support from Acceleron, outside the submitted work.

  • Received September 17, 2020.
  • Accepted September 18, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Lewis RA,
    2. Thompson AAR,
    3. Billings CG, et al.
    Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J 2020; 55: 2000041. doi:10.1183/13993003.00041-2020
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Nathan SD,
    2. Barbera JA,
    3. Gaine SP, et al.
    Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53: 1801914. doi:10.1183/13993003.01914-2018
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Cottin V,
    2. Le Pavec J,
    3. Prévot G, et al.
    Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105–111. doi:10.1183/09031936.00038709
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Chandra S,
    2. Shah SJ,
    3. Thenappan T, et al.
    Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant 2010; 29: 181–187. doi:10.1016/j.healun.2009.07.005
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Trip P,
    2. Nossent EJ,
    3. de Man FS, et al.
    Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J 2013; 42: 1575–1585. doi:10.1183/09031936.00184412
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Olsson KM,
    2. Fuge J,
    3. Meyer K, et al.
    More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. Eur Respir J 2017; 50: 1700354. doi:10.1183/13993003.00354-2017
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Hoeper MM,
    2. Meyer K,
    3. Rademacher J, et al.
    Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail 2016; 4: 441–449. doi:10.1016/j.jchf.2015.12.016
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Chaouat A,
    2. Bugnet A-S,
    3. Kadaoui N, et al.
    Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189–194. doi:10.1164/rccm.200401-006OC
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Balasubramanian A,
    2. Kolb TM,
    3. Damico RL, et al.
    Diffusing capacity is an independent predictor of outcomes in pulmonary hypertension associated with COPD. Chest 2020; 158: 722–734. doi:10.1016/j.chest.2020.02.047
    OpenUrl
  10. ↵
    1. Hamada K,
    2. Nagai S,
    3. Tanaka S, et al.
    Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 650–656. doi:10.1378/chest.06-1466
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Godinas L,
    2. Amar D,
    3. Montani D, et al.
    Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. J Heart Lung Transplant 2016; 35: 647–656. doi:10.1016/j.healun.2015.12.022
    OpenUrl
  12. ↵
    1. Hoeper MM,
    2. Vonk-Noordegraaf A
    . Is there a vanishing pulmonary capillary syndrome? Lancet Respir Med 2017; 5: 676–678. doi:10.1016/S2213-2600(17)30291-6
    OpenUrl
  13. ↵
    1. Seimetz M,
    2. Parajuli N,
    3. Pichl A, et al.
    Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147: 293–305. doi:10.1016/j.cell.2011.08.035
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 5 Table of Contents
European Respiratory Journal: 56 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mild parenchymal lung disease is still lung disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Mild parenchymal lung disease is still lung disease
Laurent Godinas, Sergio Harari, Joan A. Barberà, David Montani
European Respiratory Journal Nov 2020, 56 (5) 2003542; DOI: 10.1183/13993003.03542-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mild parenchymal lung disease is still lung disease
Laurent Godinas, Sergio Harari, Joan A. Barberà, David Montani
European Respiratory Journal Nov 2020, 56 (5) 2003542; DOI: 10.1183/13993003.03542-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society